Diagnostic value of anti‐citrullinated α‐enolase peptide 1 antibody in patients with rheumatoid arthritis: A systematic review and meta‐analysis
Open Access
- 13 March 2021
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (5) , 633-646
Abstract
Aim To evaluate the diagnostic value of anti‐citrullinated α‐enolase peptide 1 (anti‐CEP 1) antibody in patients with rheumatoid arthritis (RA) by conducting a systematic review and meta‐analysis. Methods The PubMed, Web of Science, Embase, Scopus, and Cochrane Library databases were searched for relevant studies published until September 23, 2020. A bivariate mixed‐effects model was used to calculate the diagnostic indices from primary data of eligible studies. We performed meta‐regression and subgroup analysis to explore the sources of heterogeneity. Results Twenty‐four articles, with a total of 17 380 patients with RA and 7505 control participants, met the criteria for inclusion in the meta‐analysis. The pooled sensitivity, specificity, and positive and negative likelihood ratios for the anti‐CEP 1 antibody were 44% (95% CI: 38%‐51%), 97% (95% CI: 96%‐98%), and 14.81 (95% CI: 10.66‐20.57) and 0.57 (95% CI: 0.52‐0.64), respectively. The pooled positive and negative predictive values were 0.96 (95% CI: 0.95‐0.97) and 0.53 (95% CI: 0.43‐0.63), respectively. The area under the summary receiver operating characteristic curve was 0.86. Meta‐regression indicated that the anti‐CEP 1 antibody detection method may be a source of heterogeneity. The subgroup analysis of the group in which the anti‐CEP 1 antibody was detected by using a commercial enzyme‐linked immunosorbent assay (ELISA) kit had a sensitivity of 59% (95% CI: 50%‐68%) and a specificity of 93% (95% CI: 85%‐97%). Conclusions The anti‐CEP 1 antibody had moderate RA diagnostic value with relatively low sensitivity and high specificity. An ELISA may increase the RA diagnostic sensitivity.Keywords
Funding Information
- National Natural Science Foundation of China (81671618, 81871302)
This publication has 48 references indexed in Scilit:
- Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritisClinical and Experimental Immunology, 2013
- Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice: a prospective cohort studyScandinavian Journal of Rheumatology, 2013
- Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptidesArthritis Research & Therapy, 2012
- Association of anti–citrullinated vimentin and anti–citrullinated α‐enolase antibodies with subsets of rheumatoid arthritisArthritis & Rheumatism, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritisArthritis & Rheumatism, 2010
- Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patientsArthritis & Rheumatism, 2009
- Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 allelesAnnals of the Rheumatic Diseases, 2009
- Evolutionarily conserved antigens in autoimmune disease: Implications for an infective aetiologyThe International Journal of Biochemistry & Cell Biology, 2009
- Antibodies to citrullinated α‐enolase peptide 1 are specific for rheumatoid arthritis and cross‐react with bacterial enolaseArthritis & Rheumatism, 2008